An estimated 7.4 million Americans aged 65 and older are living with Alzheimer’s disease in 2026, according to the Alzheimer’s Association — making it the most common form of dementia and the cause of an estimated 60–80% of dementia cases. The condition is not normal aging; it is a progressive neurodegenerative disorder linked to abnormal protein accumulation in the brain. There is still no cure, but recent years have brought the first FDA-approved disease-modifying therapies in two decades, along with more accurate — and increasingly less invasive — ways to detect the disease earlier. If you or a family member is facing memory concerns, please know that help and support are available, and you are not alone.
This guide covers what Alzheimer’s actually is, how it progresses, how it is diagnosed, and what treatments and supports exist today. For more on related conditions, see our medical conditions hub and our comprehensive dementia guide.
When to seek emergency care: Sudden cognitive changes, particularly if accompanied by weakness, slurred speech, severe headache, or vision changes, can indicate a stroke and warrant immediate emergency evaluation (call 911). Severe behavioral disturbance, delirium, or any thoughts of self-harm — including in exhausted caregivers — warrant urgent attention; the 988 Suicide and Crisis Lifeline is available 24/7 by call or text.
What Alzheimer’s Disease Is
Alzheimer’s is a progressive brain disorder characterized by the accumulation of amyloid plaques and tau neurofibrillary tangles. These abnormal protein deposits disrupt communication between nerve cells, trigger inflammation, and ultimately cause neuronal death, particularly in the hippocampus and cortical regions that control memory, language, and judgment.
Per National Institute on Aging data, Alzheimer’s prevalence rises sharply with age — affecting roughly 5% of people 65–74, about 13% of those 75–84, and around a third of those 85 and older. The underlying disease process is thought to begin 15–20 years before clinical symptoms appear, which is part of why earlier detection has become such an active area of research.
Early Warning Signs
The earliest symptoms typically involve recent-memory loss that disrupts daily life — repeating questions, missing appointments, struggling to follow a familiar recipe, or getting lost in familiar places. These are different from normal age-related forgetting, such as occasionally misplacing keys or taking a moment longer to recall a name.
Other early signs include difficulty completing familiar tasks, trouble with words in speaking or writing, decreased judgment (financial mistakes, falling for scams), withdrawal from work or social activities, and changes in mood or personality. The Alzheimer’s Association describes 10 warning signs that help distinguish concerning changes from typical aging. Noticing several of these — especially a change from a person’s usual self — is a reason to seek evaluation, not a reason to panic; many causes of memory change are treatable.
Symptoms vs. Normal Aging
It is normal to occasionally forget a name and remember it later, misplace items and retrace steps to find them, or need help with a new device. What is not typical aging is forgetting recently learned information repeatedly, losing the ability to manage tasks you have done for years, becoming disoriented in familiar surroundings, or withdrawing because keeping up has become hard. The distinction is about pattern, progression, and impact on daily function — and it is a clinician, not a checklist, who should make the call.
The Seven Stages
The Reisberg Global Deterioration Scale describes seven stages, though clinicians more often use the simpler categories of mild, moderate, and severe. Stages 1–2 represent normal cognition or subjective concerns without objective decline. Stage 3 (mild cognitive impairment) involves measurable deficits that family may notice, with daily functioning largely intact.
Stage 4 (mild Alzheimer’s) brings clear decline in instrumental activities — managing finances, traveling alone, complex meal preparation. Stage 5 (moderate) requires help with activities such as choosing appropriate clothing. Stage 6 (moderately severe) requires assistance with personal care, including bathing and toileting. Stage 7 (severe) involves loss of speech, mobility, and the ability to feed oneself.
Average duration from diagnosis to death is often cited as 4–8 years, but some people live 20 years with the disease. Progression rate varies substantially among individuals, and no two journeys look exactly alike.
Causes and Risk Factors
Most Alzheimer’s cases are sporadic, with age the strongest risk factor. The APOE4 gene variant raises risk: one copy roughly triples lifetime risk, and two copies (about 2–3% of the population) raise risk considerably more. Per Mayo Clinic, less than 1% of cases are early-onset (before 65), and a small fraction of these are caused by autosomal dominant mutations in the APP, PSEN1, or PSEN2 genes.
Modifiable risk factors include cardiovascular disease, high blood pressure, diabetes, obesity, smoking, physical inactivity, social isolation, depression, hearing loss, and head injury. The 2024 Lancet Commission report estimated that addressing 14 modifiable factors could, in principle, prevent or delay a large share of dementia cases worldwide — an encouraging finding, even though risk reduction is not a guarantee for any individual.
Diagnosis
Diagnosis combines clinical assessment, cognitive testing, structural brain imaging (MRI or CT), and, increasingly, biomarker testing. Cognitive screens like the MoCA (Montreal Cognitive Assessment) and MMSE quantify deficits, and comprehensive neuropsychological testing characterizes the pattern of impairment.
Biomarker advances have reshaped diagnosis. Amyloid PET scans, cerebrospinal fluid (CSF) testing for amyloid and tau, and newer blood-based biomarker tests can help confirm Alzheimer’s pathology and distinguish it from other causes of dementia such as vascular dementia, Lewy body dementia, frontotemporal dementia, and Parkinson’s disease dementia. Blood tests are an especially fast-moving area — the FDA has begun clearing plasma biomarker tests (such as those measuring a pTau217/amyloid ratio) to aid diagnosis in appropriate patients, and availability is expanding. Because this field is changing quickly, verify what is currently available and covered, and remember that these tests are meant to support, not replace, a clinician’s evaluation. A proper workup also rules out reversible mimics of dementia — vitamin B12 deficiency, hypothyroidism, normal-pressure hydrocephalus, depression, sleep disorders, and medication side effects — some of which are fully treatable.
Treatment Options
It is important to say clearly: there is no cure for Alzheimer’s disease, and no treatment can stop or reverse it. What treatments can do is ease symptoms for a time and, in early disease, modestly slow progression. Decisions about any medication should be made with the treating clinician, and the notes below are for understanding — not a guide to dosing.
Symptomatic medications include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild-to-moderate disease and memantine for moderate-to-severe disease. These produce modest, temporary symptomatic benefit in a portion of patients and do not change the underlying disease. Generic cholinesterase inhibitors are relatively inexpensive.
Disease-modifying anti-amyloid antibodies are the first treatments that target the underlying pathology. Lecanemab (Leqembi) received traditional FDA approval in 2023, and donanemab (Kisunla) in 2024. In clinical trials, both reduced amyloid plaques and slowed cognitive decline by roughly a quarter to a third over about 18 months — a meaningful but modest effect — in early-stage Alzheimer’s. These medicines are strictly prescriber-directed and are appropriate only for people with early symptomatic disease (mild cognitive impairment or mild dementia) and confirmed amyloid on PET or CSF/appropriate testing. They require careful patient selection and serial MRI monitoring for amyloid-related imaging abnormalities (ARIA) — brain swelling or small hemorrhages — which affect a notable share of treated patients and can occasionally be serious. Risk is higher in APOE4 carriers, which is why genetic and imaging assessment factor into the decision. They are not suitable for everyone, and they are delivered as scheduled infusions under specialist supervision. Costs are substantial (often cited around $26,000–$32,000 per year before scans and infusion fees), and Medicare covers these treatments for eligible patients with confirmed amyloid pathology who meet monitoring requirements. Per Cleveland Clinic, careful selection and monitoring are essential.
Behavioral Symptoms
Roughly 90% of people with Alzheimer’s develop behavioral and psychological symptoms — agitation, depression, anxiety, sleep disturbance, hallucinations, or paranoia — at some point. Non-pharmacologic approaches (consistent routines, a simplified and calm environment, identifying and removing triggers, addressing pain or unmet needs) are first-line and often the most effective and safest. When medication is considered, it is chosen and monitored by a clinician: brexpiprazole received FDA approval in 2023 for agitation associated with Alzheimer’s dementia, and antidepressants such as SSRIs may help with depression and some agitation. Antipsychotics carry important safety warnings in older adults with dementia and are used cautiously, so these choices belong with the care team.
Caregiving and Support
Alzheimer’s affects entire families, and caring for someone can be one of the hardest things a person ever does. Caregiving demands often average many hours a day in the moderate stages, and caregiver depression rates run roughly twice those of the general population — so caring for the caregiver is not optional. Adult day programs, respite care, home health services, support groups, and assisted-living memory care can all help share the load.
The Alzheimer’s Association operates a free 24/7 Helpline at 1-800-272-3900, offering support, care consultation, and referrals to local resources in many languages. It is a genuine, staffed line — please use it. Long-term care is also a major financial reality: nursing-home memory care can cost tens of thousands of dollars per year and often far more, and traditional Medicare does not cover long-term custodial care, which leads many families to navigate Medicaid eligibility or long-term-care insurance. Planning early, while the person can participate, makes a real difference.
Advance Planning and Safety
Because Alzheimer’s is progressive, early planning is an act of care. When possible, put advance directives, a healthcare proxy, and financial or durable power of attorney in place while the person can still express their wishes. Practical safety steps — medication management support, removing driving risks when the time comes, home modifications to prevent falls and wandering, ID/location tools, and simplifying daily routines — help people stay safe and as independent as possible for as long as possible. These conversations are difficult, but families consistently say that having plans in place brought relief rather than regret.
Lifestyle and Brain Health
Multiple modifiable factors are associated with Alzheimer’s risk. Regular aerobic exercise, Mediterranean or MIND diet patterns, controlling blood pressure and diabetes, treating hearing loss, maintaining social connection, staying cognitively engaged, getting adequate sleep, and avoiding head injury all show associations with reduced dementia risk in observational studies.
The FINGER trial and similar multidomain intervention studies suggest that combining these strategies can produce meaningful benefit. None of these constitutes guaranteed prevention, but the same habits that support cardiovascular and metabolic health also support brain health — so they are worth pursuing regardless.
When to See a Doctor
Memory or cognitive concerns raised by the patient or family — particularly when they affect daily activities — warrant evaluation. Primary care can begin the workup; neurology, geriatric medicine, or memory-disorder clinics offer comprehensive assessment. Earlier diagnosis matters more than ever, both because the newer disease-modifying treatments work only in early-stage disease and because early diagnosis creates time for planning, support, and treating any reversible contributors.
Workup costs vary. Cognitive testing is typically covered by Medicare. Amyloid PET imaging without insurance can run several thousand dollars; with Medicare coverage, out-of-pocket costs are typically much lower for eligible patients. Emerging blood-based tests may lower the barrier to earlier assessment over time. Telehealth-based memory clinics have also expanded access to specialty care in many areas.
Frequently Asked Questions
Is Alzheimer’s hereditary?
Most cases are not directly inherited. The APOE4 gene variant raises risk substantially but does not guarantee disease, and many people with the disease have no known family history. Less than 1% of cases involve dominantly inherited gene mutations, which typically cause early-onset disease. A family history increases risk modestly.
What’s the difference between Alzheimer’s and dementia?
Dementia is an umbrella term for cognitive decline severe enough to impair daily function. Alzheimer’s is the specific underlying disease behind an estimated 60–80% of dementia cases. Other causes include vascular dementia, Lewy body dementia, and frontotemporal dementia — see our dementia guide for the full picture.
Do anti-amyloid drugs cure Alzheimer’s?
No. Lecanemab and donanemab slow decline by roughly a quarter to a third over about 18 months in early-stage patients who meet eligibility criteria. They do not reverse existing damage or restore normal cognition, and they require confirmed amyloid and MRI monitoring for side effects. They are the first disease-modifying options and may lead to better therapies over time.
Can Alzheimer’s be prevented?
No intervention prevents Alzheimer’s with certainty, but several modifiable risk factors influence risk. Cardiovascular health, exercise, a healthy diet, social engagement, good sleep, treating hearing loss, and avoiding head injury are all associated with lower dementia risk and are worthwhile for overall health.
Is there any hope after a diagnosis?
Yes. While there is no cure, early diagnosis opens the door to treatment eligibility, symptom management, planning, and strong support networks. Many people live meaningfully for years, and the Alzheimer’s Association Helpline (1-800-272-3900) can connect families with practical help right away.
TL;DR: Alzheimer’s is a progressive brain disease and the most common cause of dementia (about 7.4 million Americans age 65+ in 2026). There is no cure. Symptomatic medicines (cholinesterase inhibitors, memantine) can ease symptoms for a time, and anti-amyloid antibodies (lecanemab/Leqembi, donanemab/Kisunla) can modestly slow decline in early, amyloid-confirmed disease — these are prescriber-directed and require MRI monitoring for ARIA. Diagnosis is clinical plus testing, with blood biomarkers emerging (verify current availability). Early diagnosis, caregiver support, and advance planning matter enormously. The Alzheimer’s Association 24/7 Helpline is 1-800-272-3900.
This article is general information, not medical advice, and includes no dosing guidance. Diagnosis and every treatment decision should be made with a qualified clinician who knows the full situation. In an emergency call 911; for crisis support call or text 988.
The Bottom Line
Alzheimer’s disease is progressive and, for now, incurable — but it is increasingly understood, and there are more options and more support than ever before. Earlier diagnosis matters both for access to disease-modifying therapies in early-stage disease and for planning. Symptomatic medications, anti-amyloid drugs for carefully selected patients, thoughtful behavioral approaches, advance planning, and strong caregiver support can together shape the journey. If memory concerns are arising, a primary care or specialty evaluation is the right first step — and the Alzheimer’s Association Helpline at 1-800-272-3900 is there whenever you need it.
Sources
- Alzheimer’s Association — 2026 Alzheimer’s Disease Facts and Figures; 24/7 Helpline (1-800-272-3900); 10 warning signs (alz.org)
- National Institute on Aging — Alzheimer’s Disease Fact Sheet (nia.nih.gov)
- MedlinePlus, U.S. National Library of Medicine — Alzheimer’s disease overview (medlineplus.gov)
- U.S. Food and Drug Administration — approvals of lecanemab, donanemab, and brexpiprazole; clearance of plasma biomarker tests (fda.gov)